Dassault just paid $2B for AI that processes 12M patient safety cases annually

Dassault Systèmes just paid $1.8 billion cash plus a $200 million AI earnout for ArisGlobal.

The deal closed at 10x forward revenue. Nordic Capital bought the company for $700M in 2019.

ArisGlobal isn't a household name. But half of the Top 50 biopharma companies run their drug safety, regulatory submissions, and quality processes through it.

12 million patient safety cases flow through the platform every year.

The AI layer is what justifies the price. ArisGlobal's NavaX platform uses generative AI to automate compliance workflows. The company claims 30%+ productivity gains.

Dassault is betting that AI-native compliance software will dominate a market projected to reach $7.5 billion by 2030.

This is the new playbook for enterprise AI in regulated industries. Legacy software firms are buying AI-native platforms rather than building them. SAP did it. Adobe did it. Now Dassault is doing it.

The strategic logic is consolidation. Dassault already owns Medidata for clinical trials. ArisGlobal handles regulatory and safety. Together they claim a single-vendor stack spanning discovery through post-market surveillance.

Audit your compliance vendor landscape today. If your drug safety, regulatory, and quality systems are fragmented across multiple vendors, you're about to face a competitor that offers all three under one contract. Switching costs just went up for every standalone tool in life sciences.